MIDOS: a novel stochastic model towards a treatment planning system for microsphere dosimetry in liver tumors.
Microspheres
Radioembolization
Segmentectomy
Tumor uptake
Yttrium-90
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
29 Dec 2023
29 Dec 2023
Historique:
received:
24
08
2023
accepted:
08
12
2023
medline:
29
12
2023
pubmed:
29
12
2023
entrez:
28
12
2023
Statut:
aheadofprint
Résumé
Transarterial radioembolization (TARE) procedures treat liver tumors by injecting radioactive microspheres into the hepatic artery. Currently, there is a critical need to optimize TARE towards a personalized dosimetry approach. To this aim, we present a novel microsphere dosimetry (MIDOS) stochastic model to estimate the activity delivered to the tumor(s), normal liver, and lung. MIDOS incorporates adult male/female liver computational phantoms with the hepatic arterial, hepatic portal venous, and hepatic venous vascular trees. Tumors can be placed in both models at user discretion. The perfusion of microspheres follows cluster patterns, and a Markov chain approach was applied to microsphere navigation, with the terminal location of microspheres determined to be in either normal hepatic parenchyma, hepatic tumor, or lung. A tumor uptake model was implemented to determine if microspheres get lodged in the tumor, and a probability was included in determining the shunt of microspheres to the lung. A sensitivity analysis of the model parameters was performed, and radiation segmentectomy/lobectomy procedures were simulated over a wide range of activity perfused. Then, the impact of using different microspheres, i.e., SIR-Sphere®, TheraSphere®, and QuiremSphere®, on the tumor-to-normal ratio (TNR), lung shunt fraction (LSF), and mean absorbed dose was analyzed. Highly vascularized tumors translated into increased TNR. Treatment results (TNR and LSF) were significantly more variable for microspheres with high particle load. In our scenarios with 1.5 GBq perfusion, TNR was maximum for TheraSphere® at calibration time in segmentectomy/lobar technique, for SIR-Sphere® at 1-3 days post-calibration, and regarding QuiremSphere® at 3 days post-calibration. This novel approach is a decisive step towards developing a personalized dosimetry framework for TARE. MIDOS assists in making clinical decisions in TARE treatment planning by assessing various delivery parameters and simulating different tumor uptakes. MIDOS offers evaluation of treatment outcomes, such as TNR and LSF, and quantitative scenario-specific decisions.
Identifiants
pubmed: 38155237
doi: 10.1007/s00259-023-06567-9
pii: 10.1007/s00259-023-06567-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bastiaannet R, Kappadath SC, Kunnen B, Braat AJAT, Lam MGEH, de Jong HWAM. The physics of radioembolization. EJNMMI Phys. 2018;5:22.
doi: 10.1186/s40658-018-0221-z
pubmed: 30386924
pmcid: 6212377
Kim SP, Cohalan C, Kopek N, Enger SA. A guide to 90Y radioembolization and its dosimetry. Phys Med. 2019;68:132–45.
doi: 10.1016/j.ejmp.2019.09.236
pubmed: 31785502
Gulec SA, McGoron AJ. Radiomicrosphere dosimetry: principles and current state of the art. Semin Nucl Med. 2022;52:215–28.
doi: 10.1053/j.semnuclmed.2021.12.009
pubmed: 35148897
Knight GM, Gordon AC, Gates V, Talwar A, Riaz A, Salem R, et al. Evolution of personalized dosimetry for radioembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2023;34:1214–25.
doi: 10.1016/j.jvir.2023.03.011
pubmed: 36977431
Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman DE, Loehr SP, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412–25.
doi: 10.1016/j.ijrobp.2005.12.051
pubmed: 16690429
Malhotra A, Liu DM, Talenfeld AD. Radiation segmentectomy and radiation lobectomy: a practical review of techniques. Tech Vasc Interv Radiol. 2019;22:49–57.
doi: 10.1053/j.tvir.2019.02.003
pubmed: 31079710
Westcott MA, Coldwell DM, Liu DM, Zikria JF. The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres. Adv Radiat Oncol. 2016;1:351–64.
doi: 10.1016/j.adro.2016.08.003
pubmed: 28740906
pmcid: 5514171
Weber M, Lam M, Chiesa C, Konijnenberg M, Cremonesi M, Flamen P, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49:1682–99.
doi: 10.1007/s00259-021-05600-z
pubmed: 35146577
pmcid: 8940802
Reinders MTM, Smits MLJ, van Roekel C, Braat AJAT. Holmium-166 microsphere radioembolization of hepatic malignancies. Semin Nucl Med. 2019;49:237–43.
doi: 10.1053/j.semnuclmed.2019.01.008
pubmed: 30954190
Ilhan H, Goritschan A, Paprottka P, Jakobs TF, Fendler WP, Todica A, et al. Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in radioembolization of primary and secondary hepatic tumors. J Nucl Med. 2015;56:1654–60.
doi: 10.2967/jnumed.115.162685
pubmed: 26315830
Haste P, Tann M, Persohn S, LaRoche T, Aaron V, Mauxion T, et al. Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission CT and posttreatment positron emission tomography/CT. J Vasc Interv Radiol. 2017;28:722-730.e1.
doi: 10.1016/j.jvir.2016.12.1221
pubmed: 28238581
Bertolet A, Wehrenberg-Klee E, Bobic M, Grassberger C, Perl J, Paganetti H, et al. Pre- and post-treatment image-based dosimetry in 90Y-microsphere radioembolization using the TOPAS Monte Carlo toolkit. Phys Med Biol. 2021;66:244002.
doi: 10.1088/1361-6560/ac43fd
Villalobos A, Cheng B, Wagstaff W, Sethi I, Bercu Z, Schuster DM, et al. Tumor-to-normal ratio relationship between planning technetium-99 macroaggregated albumin and posttherapy yttrium-90 bremsstrahlung SPECT/CT. J Vasc Interv Radiol. 2021;32:752–60.
doi: 10.1016/j.jvir.2020.12.023
pubmed: 33642158
Young S, Chen T, Flanagan S, Golzarian J, Sanghvi T. Realized tumor to normal ratios in hepatocellular carcinoma patients undergoing transarterial radioembolization: a retrospective evaluation. Eur Radiol. 2022;32:4160–7.
doi: 10.1007/s00330-021-08501-9
pubmed: 35032212
Villalobos A, Arndt L, Cheng B, Dabbous H, Loya M, Majdalany B, et al. Yttrium-90 radiation segmentectomy of hepatocellular carcinoma: a comparative study of the effectiveness, safety, and dosimetry of glass vs. resin-based microspheres. J Vasc Interv Radiol. 2023;34:1226–34.
doi: 10.1016/j.jvir.2023.02.030
pubmed: 36958669
Pasciak AS, Abiola G, Liddell RP, Crookston N, Besharati S, Donahue D, et al. The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure. Eur J Nucl Med Mol Imaging. 2020;47:816–27.
doi: 10.1007/s00259-019-04588-x
pubmed: 31741021
Maxwell AWP, Mendoza HG, Sellitti MJ, Camacho JC, Deipolyi AR, Ziv E, et al. Optimizing 90Y particle density improves outcomes after radioembolization. Cardiovasc Intervent Radiol. 2022;45:958–69.
doi: 10.1007/s00270-022-03139-6
pubmed: 35459960
pmcid: 10103908
Boas FE, Maxwell AWP. Beyond mean tumor dose: the importance of particle density in radioembolization. J Vasc Interv Radiol. 2023;34:1235–6.
doi: 10.1016/j.jvir.2023.03.005
pubmed: 36958670
Aramburu J, Antón R, Rodríguez-Fraile M, Sangro B, Bilbao JI. Computational fluid dynamics modeling of liver radioembolization: a review. Cardiovasc Intervent Radiol Springer. 2022;45:12–20.
doi: 10.1007/s00270-021-02956-5
Toskich B, Lewandowski RJ. Computational modeling of radioembolization: how to calculate infinity. Cardiovasc Intervent Radiol. Springer; 2021. pp. 2020–1.
Miller SR, Jernigan SR, Abraham RJ, Buckner GD. Comparison of bolus versus dual-syringe administration systems on glass yttrium-90 microsphere deposition in an in vitro microvascular hepatic tumor model. J Vasc Interv Radiol. 2023;34:11–20.
doi: 10.1016/j.jvir.2022.07.032
pubmed: 36108898
Crookston NR, Fung GSK, Frey EC. Development of a customizable hepatic arterial tree and particle transport model for use in treatment planning. IEEE Trans Radiat Plasma Med Sci. 2019;3:31–7.
doi: 10.1109/TRPMS.2018.2842463
pubmed: 33829118
Walrand S, Hesse M, Chiesa C, Lhommel R, Jamar F. The low hepatic toxicity per gray of 90Y glass microspheres is linked to their transport in the arterial tree favoring a nonuniform trapping as observed in posttherapy PET imaging. J Nucl Med. 2014;55:135–40.
doi: 10.2967/jnumed.113.126839
pubmed: 24296766
Högberg J, Rizell M, Hultborn R, Svensson J, Henrikson O, Mölne J, et al. Simulation model of microsphere distribution for selective internal radiation therapy agrees with observations. Int J Radiat Oncol Biol Phys. 2016;96:414–21.
doi: 10.1016/j.ijrobp.2016.05.007
pubmed: 27475671
Pasciak AS, Bourgeois AC, Bradley YC. A microdosimetric analysis of absorbed dose to tumor as a function of number of microspheres per unit volume in 90Y Radioembolization. J Nucl Med. 2016;57:1020–6.
doi: 10.2967/jnumed.115.163444
pubmed: 26912424
Correa-Alfonso CM, Withrow JD, Domal SJ, Xing S, Shin J, Grassberger C, et al. A mesh-based model of liver vasculature: implications for improved radiation dosimetry to liver parenchyma for radiopharmaceuticals. EJNMMI Phys. 2022;9:28.
doi: 10.1186/s40658-022-00456-0
pubmed: 35416550
pmcid: 9008118
Lewandowski RJ, Minocha J, Memon K, Riaz A, Gates VL, Ryu RK, et al. Sustained safety and efficacy of extended-shelf-life 90Y glass microspheres: long-term follow-up in a 134-patient cohort. Eur J Nucl Med Mol Imaging. 2014;41:486–93.
doi: 10.1007/s00259-013-2575-8
pubmed: 24114004
Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90 Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med. 2006;47.
Campbell AM, Bailey IH, Burton MA. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol. 2000;45:1023–33.
doi: 10.1088/0031-9155/45/4/316
pubmed: 10795989
Högberg J, Rizell M, Hultborn R, Svensson J, Henrikson O, Mölne J, et al. Heterogeneity of microsphere distribution in resected liver and tumour tissue following selective intrahepatic radiotherapy. EJNMMI Res. 2014;4.
Högberg J, Rizell M, Hultborn R, Svensson J, Henrikson O, Mölne J, et al. Increased absorbed liver dose in selective internal radiation therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity. EJNMMI Phys. 2015;2:1–17.
doi: 10.1186/s40658-015-0113-4
Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of 90Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60:1552–63.
doi: 10.1016/j.ijrobp.2004.09.004
pubmed: 15590187
Schiro BJ, Amour ES, Harnain C, Gandhi RT. Management of high hepatopulmonary shunts in the setting of Y90 radioembolization. Tech Vasc Interv Radiol. 2019;22:58–62.
doi: 10.1053/j.tvir.2019.02.004
pubmed: 31079711
Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization. Front Oncol. 2014;4.
Van Roekel C, Van Den Hoven AF, Bastiaannet R, Bruijnen RCG, Braat AJAT, De Keizer B, et al. Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization-a prospective, within-patient randomized study. Eur J Nucl Med Mol Imaging. 2021;48:1658–68.
doi: 10.1007/s00259-020-05079-0
pubmed: 33128132
Reinders MTM, van Erpecum KJ, Smits MLJ, Braat AJAT, de Bruijne J, Bruijnen R, et al. Safety and efficacy of 166Ho radioembolization in hepatocellular carcinoma: the HEPAR Primary Study. J Nucl Med. 2022;63:1891–8.
doi: 10.2967/jnumed.122.263823
pubmed: 35589409
pmcid: 9730925
van Roekel C, Harlianto NI, Braat AJAT, Prince JF, van den Hoven AF, Bruijnen RCG, et al. Evaluation of the safety and feasibility of same-day holmium-166-radioembolization simulation and treatment of hepatic metastases. J Vasc Interv Radiol. 2020;31:1593–9.
doi: 10.1016/j.jvir.2020.01.032
pubmed: 32861571
Aramburu J, Antón R, Rivas A, Ramos JC, Sangro B, Bilbao JI. Computational assessment of the effects of the catheter type on particle–hemodynamics during liver radioembolization. J Biomech. 2016;49:3705–13.
doi: 10.1016/j.jbiomech.2016.09.035
pubmed: 27751570
Lertxundi U, Aramburu J, Rodríguez-Fraile M, Sangro B, Antón R. Computational study of the microsphere concentration in blood during radioembolization. Mathematics. 2022;10:4280.
doi: 10.3390/math10224280
Aramburu J, Antón R, Rivas A, Ramos JC, Sangro B, Bilbao JI. The role of angled-tip microcatheter and microsphere injection velocity in liver radioembolization: a computational particle–hemodynamics study. Int J Numer Method Biomed Eng. 2017;33:e2895.
doi: 10.1002/cnm.2895
Taebi A, Janibek N, Goldman R, Pillai R, Vu CT, Roncali E. The impact of injection distance to bifurcations on yttrium-90 distribution in liver cancer radioembolization. J Vasc Interv Radiol. 2022;33:668–77.
doi: 10.1016/j.jvir.2022.03.006
pubmed: 35301128
pmcid: 9156550
Bomberna T, Koudehi GA, Claerebout C, Verslype C, Maleux G, Debbaut C. Transarterial drug delivery for liver cancer: numerical simulations and experimental validation of particle distribution in patient-specific livers. Expert Opin Drug Deliv. 2021;18:409–22.
doi: 10.1080/17425247.2021.1853702
pubmed: 33210955